Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites

OBJECTIVE: This prospective, dose-escalation phase I study evaluated the safety and efficacy of intraperitoneal bevacizumab in managing refractory malignant ascites and explored the recommended dose of bevacizumab for further study. METHODS: Patients with refractory malignant ascites were enrolled....

Descripción completa

Detalles Bibliográficos
Autores principales: Kou, Furong, Gong, Jifang, Li, Yan, Li, Jian, Zhang, Xiaotian, Li, Jie, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Prospective Clinical Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903826/
https://www.ncbi.nlm.nih.gov/pubmed/33616416
http://dx.doi.org/10.1177/0300060520986664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903826/
https://www.ncbi.nlm.nih.gov/pubmed/33616416
http://dx.doi.org/10.1177/0300060520986664

Ejemplares similares